Depuy Hip Lawyer

The Senate Unique Committee on Aging held a hearing on April 13th concerning how medical devices are approved for sale by the FDA. The hip replacement recall of the DePuy ASR was also discussed at the hearing, placing emphasis on the importance of the testing and better post-market surveillance of medical devices.

The government agency has two processes to approve medical devices: the Premarket Approval Method requires clinical trials, whilst the quickly-track method, the 501(k), only calls for that a product is comparable to other approved merchandise already on the marketplace. The DePuy ASR hip replacement was approved through the 501(k) approach, which needed minimal testing of the device. The FDA’s quickly-track procedure has come under scrutiny due to the fact hip implants, which are regarded as a high-threat device, are cleared through the non-rigorous 501(k) method.

The hearing included testimony from patient-safety advocates, market representatives, and a ASR hip implant recipient. The patient disclosed that her medical doctor had received $600,000 in consulting fees from DePuy Orthopaedics. The quantity, unfortunately, is consistent with the bribery complaint Johnson & Johnson, DePuy’s parent company, recently settled for $70 million. The firm admitted to bribing European doctors and well being-care providers in order to sell their goods, including the DePuy hip replacement device.

Mass Device website, which published an write-up relating to the hearing, quoted DePuy’s Director of Communications as stating that the organization supports efforts to strengthen patient safety, the establishment of a national joint registry in the U.S., and that DePuy would work “…with the FDA to strengthen an currently-robust approach that has worked nicely for 3 decades and evolved, when suitable, to far better serve patients.” Considering the amount of recalls of 501(k) approved products, it is troubling that DePuy would call the procedure ‘robust,’ especially because the company had its own product recalled. Although there is pressure from the medical device business to lighten the approval burden, patient safety must not be neglected in order to make money, only to have the device recalled later. DePuy not only developed a faulty device, but also failed to timely warn surgeons and patients of the wellness dangers of the device. The hip replacement recall of the ASR, which was implanted in over 30,000 patients in the U.S., helped shed a light on the significance of clinical trials and tougher FDA approval process to make sure patient safety.

Depuy hip lawyers can help those who have suffered from a defective Depuy hip replacement device file a <"http://tannadewindt3380.blogspace.fr/tag/Depuy+Hip+Lawsuit/ ">depuy hip lawsuit